The journal of allergy and clinical immunology. Global最新文献

{"title":"Outcomes of pediatric patients with suspected allergies to COVID-19 vaccines","authors":"Qin Ying Lim MBBS ,&nbsp;Tsun Ming Lau BSc ,&nbsp;Sophie H.Y. Lai MBBS ,&nbsp;Gilbert T. Chua MBBS ,&nbsp;Kaiyue Zhang MPH ,&nbsp;Jennifer H.Y. Lam BSc (Hon) ,&nbsp;Wilfred H.S. Wong PhD ,&nbsp;Yu Lung Lau MD (Hon) ,&nbsp;Jaime S. Rosa Duque MD","doi":"10.1016/j.jacig.2024.100387","DOIUrl":"10.1016/j.jacig.2024.100387","url":null,"abstract":"<div><h3>Background</h3><div>Adverse effects following immunizations (AEFIs) can contribute to vaccine hesitancy.</div></div><div><h3>Objective</h3><div>We evaluated clinical outcomes of AEFIs subsequent to administration of the coronavirus disease 2019 (COVID-19) vaccine at 2 pediatric allergy centers.</div></div><div><h3>Methods</h3><div>Data on pediatric patients referred for COVID-19 AEFI concerns between March 2021 and October 2022 were reviewed. The collected data included patient demographics, clinical characteristics, outcomes of prior COVID-19 vaccination, recommendations after consultation, and outcomes of revaccination.</div></div><div><h3>Results</h3><div>The 163 patients were separated into 2 groups based on the absence (n = 89 [54.6%]) or presence (n = 74 [45.4%]) of prior COVID-19–related AEFIs. The most common reason for referral without a prior AEFI was another suspected drug allergy (n = 58 [35.6%]). All patients in this group were recommended for COVID-19 vaccination. Of the 163 patients, 82 (92.1%) proceeded with vaccination, with 77 of them (93.9%) tolerating vaccination. Most of those with a prior COVID-19–related AEFI had a delayed cutaneous reaction (n = 60 [37.0%]); 1 patient (0.6%) had suspected anaphylaxis. In this group, 6 (8.1%) were advised to postpone COVID-19 vaccination until their debilitating skin conditions had improved in response to further treatment, whereas 45 (77.6%) tolerated subsequent vaccination to the same or an alternate COVID-19 vaccine type. The most common AEFI on revaccination was urticaria (in 8 of 11 patients [72.7%]). AEFI on revaccination was significantly associated with a history of spontaneous urticaria or angioedema (relative risk = 3.6 [95% CI = 1.30-9.99]; <em>P</em> = .020) and urticaria following COVID-19 vaccination previously (relative risk = 4.12 [95% CI = 1.22-13.87]; <em>P</em> = .017).</div></div><div><h3>Conclusions</h3><div>Children with a history of urticaria or angioedema related or unrelated to prior COVID-19 vaccination were at higher risk of a COVID-19–related AEFI on revaccination, although most were able to complete the vaccination series under the management of our immunology/allergy service.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 1","pages":"Article 100387"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ChatGPT as a source of information on asthma","authors":"Amnuay Kleebayoon PhD ,&nbsp;Viroj Wiwanitkit MD","doi":"10.1016/j.jacig.2024.100390","DOIUrl":"10.1016/j.jacig.2024.100390","url":null,"abstract":"","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 1","pages":"Article 100390"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologic therapies targeting type 2 cytokines are effective at improving asthma symptoms and control—a systematic review and meta-analysis","authors":"Rebecca E. Bignold PhD,&nbsp;Hannah Busby BSc,&nbsp;Jenny Holloway BSc,&nbsp;Aaishah Kasu BSc,&nbsp;Sonia Sian BSc,&nbsp;Jill R. Johnson PhD","doi":"10.1016/j.jacig.2024.100374","DOIUrl":"10.1016/j.jacig.2024.100374","url":null,"abstract":"<div><h3>Background</h3><div>Allergic asthma is a highly prevalent chronic inflammatory disease driven by aeroallergen exposure. In severe asthma, the current standard of care does not fully control disease symptoms, indicating an unmet clinical need. Biologic therapies targeting cytokines IL-4, IL-5, and IL-13 have been shown to provide benefits to asthmatic patients over currently existing asthma treatments.</div></div><div><h3>Objective</h3><div>We sought to review the effects of recently developed biologic therapies for asthma treatment.</div></div><div><h3>Methods</h3><div>In this meta-analysis, the impact of IL-5 and IL-4/IL-13 biologic inhibitors was critically appraised considering overall lung function, symptom control, and oral corticosteroid use in asthmatic patients. Trials were identified using PubMed, Web of Science, Scopus, and <span><span>clinicaltrials.gov</span><svg><path></path></svg></span>. Clinical trials assessing severe asthmatic participants older than 12 years were included.</div></div><div><h3>Results</h3><div>The meta-analysis included 6600 participants from 14 trials published in 2013 to 2020. For IL-5 inhibitors, improvements in FEV₁ (mean difference [MD], 0.11; 95% CI, 0.11 to 0.12), Asthma Control Questionnaire scores (MD, −0.4; 95% CI, −0.41 to −0.38), annual exacerbation rates (MD, −0.46; 95% CI, −0.48 to −0.45), and oral corticosteroid use (MD, −50; 95% CI, −52.58 to −47.42) favored biologic treatment. Significant improvements in FEV₁ (MD, 0.11; 95% CI, 0.10 to 0.11), Asthma Control Questionnaire scores (MD, −0.20; 95% CI, −0.22 to −0.18), and annual exacerbation rates (MD, −0.15; 95% CI, −0.16 to −0.14) were also seen with anti–IL-4/IL-13 biologic therapies. However, anti–IL-4/IL-13 inhibitors were associated with more adverse events than placebo (MD, 1.13; 95% CI, 0.97 to 1.3).</div></div><div><h3>Conclusions</h3><div>Biologic inhibitors targeting T_H2 cytokines are beneficial for improving overall asthma control.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 1","pages":"Article 100374"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11751513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three versions of an atopic dermatitis case report written by humans, artificial intelligence, or both: Identification of authorship and preferences","authors":"Mara Giavina Bianchi MD, PhD ,&nbsp;Andrew D’adario MSc ,&nbsp;Pedro Giavina Bianchi MD, PhD ,&nbsp;Birajara Soares Machado PhD","doi":"10.1016/j.jacig.2024.100373","DOIUrl":"10.1016/j.jacig.2024.100373","url":null,"abstract":"<div><h3>Background</h3><div>The use of artificial intelligence (AI) in scientific writing is rapidly increasing, raising concerns about authorship identification, content quality, and writing efficiency.</div></div><div><h3>Objectives</h3><div>This study investigates the real-world impact of ChatGPT, a large language model, on those aspects in a simulated publication scenario.</div></div><div><h3>Methods</h3><div>Forty-eight individuals representing 3 medical expertise levels (medical students, residents, and experts in allergy or dermatology) evaluated 3 blinded versions of an atopic dermatitis case report: one each human written (HUM), AI generated (AI), and combined written (COM). The survey assessed authorship, ranked their preference, and graded 13 quality criteria for each text. Time taken to generate each manuscript was also recorded.</div></div><div><h3>Results</h3><div>Authorship identification accuracy mirrored the odds at 33%. Expert participants (50.9%) demonstrated significantly higher accuracy compared to residents (27.7%) and students (19.6%, <em>P</em> &lt; .001). Participants favored AI-assisted versions (AI and COM) over HUM (<em>P</em> &lt; .001), with COM receiving the highest quality scores. COM and AI achieved 83.8% and 84.3% reduction in writing time, respectively, compared to HUM, while showing 13.9% (<em>P</em> &lt; .001) and 11.1% improvement in quality (<em>P</em> &lt; .001), respectively. However, experts assigned the lowest score for the references of the AI manuscript, potentially hindering its publication.</div></div><div><h3>Conclusion</h3><div>AI can deceptively mimic human writing, particularly for less experienced readers. Although AI-assisted writing is appealing and offers significant time savings, human oversight remains crucial to ensure accuracy, ethical considerations, and optimal quality. These findings underscore the need for transparency in AI use and highlight the potential of human-AI collaboration in the future of scientific writing.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 1","pages":"Article 100373"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food allergy has no negative impact on children’s school performance: A Swedish sibling and co-twin control study","authors":"Cecilia Lundholm PhD ,&nbsp;Hanna Karim MD ,&nbsp;Awad I. Smew MD, PhD ,&nbsp;Michael Silverman PhD ,&nbsp;Tong Gong PhD ,&nbsp;Bronwyn K. Brew PhD ,&nbsp;Catarina Almqvist MD, PhD","doi":"10.1016/j.jacig.2024.100380","DOIUrl":"10.1016/j.jacig.2024.100380","url":null,"abstract":"<div><h3>Background</h3><div>Food allergy has been shown to negatively impact children’s mental health and quality of life. However, its impact on school performance is unknown.</div></div><div><h3>Objective</h3><div>We aimed to investigate whether food allergy, severe and nonsevere, is associated with school performance when accounting for measured and unmeasured familial factors.</div></div><div><h3>Methods</h3><div>This was a register-based cohort study, with sibling controls, including all children born in Sweden 2001-5 (n = 456,164) with food allergy information based on hospital visits and prescriptions, grades, and national test results from all Swedish schools and confounders. Primary exposure was food allergy severity (none, nonsevere, or severe) in school years 7-9, and the primary outcome was total grades from year 9, with secondary exposures/outcomes also at younger ages. The primary outcome was analyzed by linear regression and, for sibling/twin control analyses, fixed effect linear regression. Results were replicated in a twin cohort (n = 31,609).</div></div><div><h3>Results</h3><div>In unadjusted and analyses adjusted for measured confounders, children with severe food allergy appeared to have better total grades than children without food allergy (β_unadjusted = 10.6 [95% confidence interval (CI), 8.6, 12.6] and β_adjusted = 5.5 [95% CI, 3.7, 7.4]). When also adjusting for unmeasured confounders shared by siblings, the difference was close to null and statistically nonsignificant (β_sibling = 1.6 [95% CI, −1.5, 4.7]; for nonsevere food allergy, β_sibling = −0.0 [95% CI, −2.2, 2.1]). The twin cohort results were similar.</div></div><div><h3>Conclusions</h3><div>We found no consistent evidence of a negative effect of food allergy, either severe or nonsevere, on school performance when adjusting for measured and unmeasured confounders shared by siblings.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 1","pages":"Article 100380"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti–IL-4Ra therapy is superior to other biologic classes in treating allergic bronchopulmonary aspergillosis","authors":"Pedro A. Lamothe MD, PhD ,&nbsp;Charles Lewis Humphrey Pruett MS ,&nbsp;Natalia Smirnova MD ,&nbsp;Aaron Shepherd MD ,&nbsp;Martin C. Runnstrom MD ,&nbsp;Jiwon Park BA ,&nbsp;Rebecca H. Zhang MS ,&nbsp;Leshan Zhao MS ,&nbsp;Colin Swenson MD ,&nbsp;F. Eun-Hyung Lee MD","doi":"10.1016/j.jacig.2024.100369","DOIUrl":"10.1016/j.jacig.2024.100369","url":null,"abstract":"<div><h3>Background</h3><div>Allergic bronchopulmonary aspergillosis (ABPA) is a disease resulting from an overactive type 2 response to <em>Aspergillus</em>. Initial studies suggest that asthma biologics can effectively treat ABPA, but it is unclear which biologic class is superior.</div></div><div><h3>Objective</h3><div>We sought to compare the effectiveness of asthma biologics in the treatment of ABPA.</div></div><div><h3>Methods</h3><div>We performed a retrospective analysis of patients with ABPA treated with asthma biologics, and measured outcomes of respiratory exacerbations, daily oral corticosteroids, and antifungals. We assessed these variables while individuals were treated with 1 of 3 biologic classes: anti-IgE, anti–IL-5/IL-5 receptor alpha (IL-5Ra), anti–IL-4 receptor alpha (IL-4Ra).</div></div><div><h3>Results</h3><div>A total of 21 patients were included in our analysis. Anti–IL-4Ra was associated with a significantly lower number of exacerbations and oral corticosteroid use compared with anti-IgE or anti–IL-5/IL-5Ra therapies. Anti–IL-4Ra also had significantly lower antifungal use than anti-IgE, and there was a trend toward lower antifungal use when compared with anti–IL-5/IL-5Ra. In a subgroup of 10 patients treated with 2 or more biologics sequentially, we found that 8 of them achieved clinical control on anti–IL-4Ra therapy after failing anti-IgE and/or anti–IL-5/IL-5Ra therapies.</div></div><div><h3>Conclusions</h3><div>Dupilumab blocks the IL-4Ra, resulting in the downstream inhibition of both IL-4 and IL-13 effector pathways. Dupilumab may benefit patients with ABPA by inhibiting the generation of airway mucus (IL-13), and by reducing local B-cell differentiation into IgE antibody–secreting cells (IL-4). On the basis of our findings and with the known molecular mechanisms of dupilumab, we believe that anti–IL-4Rα–targeted therapy may be more effective than anti-IgE or anti–IL-5/IL-5Rα therapies to treat ABPA.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 1","pages":"Article 100369"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142907970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resolution of hypogammaglobulinemia-associated recurrent Campylobacter bacteraemia after hematopoietic cell transplantation (HCT)","authors":"Emmanouil Karofylakis MD ,&nbsp;Effrossyni Gkrania-Klotsas MD, MPH, FRCP, PhD ,&nbsp;Benjamin Uttenthal MA, MBBS, PhD, MRCP, FRCPath ,&nbsp;Dinakantha Kumararatne MBBS, FRCPath, DPhil","doi":"10.1016/j.jacig.2024.100378","DOIUrl":"10.1016/j.jacig.2024.100378","url":null,"abstract":"<div><div>Primary or secondary hypogammaglobulinemia is associated with persistent norovirus and <em>Campylobacter</em> infections despite immunoglobulin replacement therapy. Allogeneic hematopoietic cell transplantation for hematologic indications can lead to immune reconstitution by correcting a previously undiagnosed concurrent primary immunodeficiency.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 1","pages":"Article 100378"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11719299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stability of diluted chlorhexidine for skin testing in drug allergy evaluations","authors":"Divya Shah MD ,&nbsp;Gabriel Cojuc-Konigsberg BS ,&nbsp;Stacy D. Brown PhD ,&nbsp;Sergio E. Chiarella MD ,&nbsp;Gerald W. Volcheck MD ,&nbsp;Hirohito Kita MD ,&nbsp;Lene H. Garvey MD, PhD (Professor) ,&nbsp;Alexei Gonzalez-Estrada MD","doi":"10.1016/j.jacig.2024.100372","DOIUrl":"10.1016/j.jacig.2024.100372","url":null,"abstract":"<div><h3>Background</h3><div>Chlorhexidine gluconate (CHX), a common cause of perioperative anaphylaxis, is frequently used for skin testing in allergy evaluations. Although CHX’s maximal nonirritating concentrations are known, the stability of its dilutions for skin testing remains unexplored, particularly when sterile water for injection (SWFI) or normal saline (NS) are used as diluents.</div></div><div><h3>Objective</h3><div>Our aim was to evaluate the stability and precipitation of CHX when diluted with SWFI or NS for drug allergy skin testing.</div></div><div><h3>Methods</h3><div>CHX dilutions (5-0.002 mg/mL) were prepared using SWFI and NS. HPLC and UV-visible spectrophotometry were used to assess stability and precipitation over 48 hours. Turbidity was measured at various time points to monitor precipitation.</div></div><div><h3>Results</h3><div>HPLC analysis showed no significant differences in peak heights between CHX-SWFI and CHX-NS dilutions. However, visible precipitation and increased turbidity (&gt;100 NTU) were observed in CHX-NS at higher concentrations (5 mg/mL) after 60 minutes. No precipitation occurred in CHX-SWFI at any concentration for 48 hours.</div></div><div><h3>Conclusion</h3><div>For CHX skin testing, SWFI is the preferred diluent at concentrations higher than 0.02 mg/mL to avoid precipitation. Using NS for the final dilution from 0.02 to 0.002 mg/mL is feasible and reduces injection pain. Except for CHX-NS at 5 mg/mL, reagents can be prepared up to 24 hours before testing.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 1","pages":"Article 100372"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11719288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obstetric penicillin allergy evaluations","authors":"Lakshmi G. Nair MD ,&nbsp;S. Shahzad Mustafa MD ,&nbsp;Allison Ramsey MD","doi":"10.1016/j.jacig.2024.100376","DOIUrl":"10.1016/j.jacig.2024.100376","url":null,"abstract":"<div><h3>Background</h3><div>Penicillin allergy is reported in 5% to 15% of the world population, with 3% to 10% of pregnant women reporting the same. However, more than 90% of these patients can tolerate penicillin after appropriate evaluation. Penicillin is indicated for various issues that arise in pregnancy, and a history of allergy can have negative individual and public health consequences.</div></div><div><h3>Objective</h3><div>Our aim was to prospectively evaluate the feasibility, safety, and select obstetric outcomes of obstetric penicillin allergy evaluations arranged through a direct referral phone line from obstetric practices to an employed allergy/immunology practice.</div></div><div><h3>Methods</h3><div>Patients were referred via direct phone line for evaluation during their antenatal visits between May 2019 and May 2022. Patients underwent skin prick testing, and those with a negative penicillin skin testing (PST) result were subjected to amoxicillin challenge. In select cases of patients with a low-risk history, direct oral challenge was performed. Data were analyzed using descriptive statistics.</div></div><div><h3>Results</h3><div>Of the 324 patients referred between May 2019 and May 2022, a total of 251 (77.5%) presented for in-office evaluations. Of those 251 patients, 239 (95.2%) underwent PST followed by oral challenge if the PST result was negative; 12 patients (4.8%) underwent direct challenge without skin testing, and all of them passed the challenge. Of the patients undergoing PST, 230 (97.2%) had a negative result and 229 tolerated subsequent oral amoxicillin doses, with 1 patient experiencing a delayed reaction to the amoxicillin. The group of patients who presented for evaluation included more people living in ZIP codes described as being of high socioeconomic status than in the no-show group (73.7% vs 63.3%).</div></div><div><h3>Conclusion</h3><div>To our knowledge, ours is the largest study to date to demonstrate the safety and feasibility of a phone line for obstetric penicillin allergy referrals. We demonstrate a better show rate than previous analyses, with most of the patients presenting for evaluation being successfully delabeled.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 1","pages":"Article 100376"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validating and utilizing dried blood spots for family screening: Screening Programme Providing Outreach for Testing Hereditary Angioedema (SPPOT-HAE)","authors":"Jane C.Y. Wong MBBS ,&nbsp;Dorothy L.Y. Lam MSc ,&nbsp;Jackie S.H. Yim MSc ,&nbsp;Elaine Lee MSc ,&nbsp;Weihong Shi MMed ,&nbsp;Valerie Chiang MBBS ,&nbsp;Philip H. Li MD","doi":"10.1016/j.jacig.2024.100381","DOIUrl":"10.1016/j.jacig.2024.100381","url":null,"abstract":"<div><h3>Background</h3><div>Hereditary angioedema (HAE) is a rare genetic disorder with potentially life-threatening consequences, traditionally diagnosed by conventional laboratory methods that can be resource intensive and inconvenient. Incorporating dried blood spot (DBS) tests may be a promising alternative for diagnosing HAE and family screening.</div></div><div><h3>Objective</h3><div>This study aimed to validate DBS with conventional laboratory assays among confirmed C1 esterase inhibitor (C1-INH) HAE patients and assess the utility of DBS in a Screening Programme Providing Outreach for Testing Hereditary Angioedema (SPPOT-HAE).</div></div><div><h3>Methods</h3><div>In part 1, 16 Chinese C1-INH-HAE patients from 7 families participated in the validation of DBS for detecting C4, C1-INH, and functional C1-INH (fC1-INH). The results were compared with conventional laboratory assays. In part 2, DBS was utilized in family screening for HAE in a large Chinese family with relatives previously refusing testing.</div></div><div><h3>Results</h3><div>The study found strong correlation between conventional assays and DBS in measuring C4 (<em>r</em> = 0.870, <em>P</em> &lt; .0001), C1-INH (<em>r</em> = 0.978, <em>P</em> &lt; .0001), and fC1-INH (<em>r</em> = 0.756, <em>P</em> &lt; .0001). There were no false-negative results from the DBS for C4, C1-INH or fC1-INH. SPPOT-HAE successfully recruited 9 additional relatives for family screening, of whom 22% were confirmed to have HAE. The use of DBS in an outreach program overcame barriers of prior family screening initiatives.</div></div><div><h3>Conclusion</h3><div>This is the first study to validate measurement of fC1-INH using DBS in C1-INH-HAE with conventional assays. An outreach program using DBS is a promising strategy overcoming previous barriers of family screening. Further large-scale, multicenter studies are required to establish the role of DBS, compare cost-effectiveness with prior strategies, and maximize diagnosis in resource-constrained countries.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 1","pages":"Article 100381"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}